Last updated: February 23, 2026
What is NDC 00003-0528?
NDC 00003-0528 is a specific drug identified through the National Drug Code system. Based on publicly available data, it corresponds to Enbrel (etanercept), a biologic medication used primarily for autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Market Overview
Therapeutic Area and Competition
Enbrel operates within the biologic disease-modifying antirheumatic drugs (DMARDs) market. It faces competition from other TNF inhibitors such as Humira (adalimumab), Remicade (infliximab), and Cimzia (certolizumab).
Market Size and Trends
The global autoimmune disease treatment market was valued at approximately $45 billion in 2022, growing at a compound annual growth rate (CAGR) of 6.2% from 2021 to 2027. Enbrel's share was estimated at 15%, corresponding to about $6.75 billion in market value in 2022.
Within the U.S., the biologic drugs segment accounts for roughly 70% of the autoimmune treatment market, with Enbrel generating $2.2 billion in 2022 sales domestically.
Regulatory and Patent Status
The original patent for Enbrel expired in 2029, with several biosimilars approved or pending approval. The entry of biosimilars in the U.S. has led to price competition, with reductions of 15-30% observed since 2020.
Price Analysis
Historical Pricing Trends
- Brand-Name Enbrel (pre-2022): Average wholesale price (AWP) was approximately $60,000 per year for a standard dosing regimen.
- Post-Biosimilar Entry (2020-2023): Prices fell by an average of 20%, with some biosimilars marketed at approximately $45,000–$50,000 annually.
Current Price Projections
Considering trend data, biosimilars are expected to continue exerting downward pressure:
| Year |
Estimated Enbrel Price (Annual) |
Biosimilar Price Range |
Market Share (%) |
| 2023 |
$50,000 – $55,000 |
$40,000 – $50,000 |
55 |
| 2024 |
$45,000 – $50,000 |
$35,000 – $45,000 |
65 |
| 2025 |
$40,000 – $45,000 |
$30,000 – $40,000 |
75 |
| 2026 |
$35,000 – $40,000 |
$25,000 – $35,000 |
85 |
Price Drivers
- Biosimilar competition remains primary factor.
- Patent expiration and regulatory approvals influence pricing.
- Reimbursement policies and payer negotiations continue to pressure list prices downward.
- Manufacturing costs for biosimilars are decreasing with advances in production technology.
Market Penetration and Adoption
Biosimilar adoption varies by region:
- U.S.: Slower due to patent litigations, brand loyalty, and payer negotiations.
- Europe: Higher biosimilar uptake, resulting in lower prices and greater market competition.
In the U.S., biosimilars are projected to reach a 70% market share by 2025, which will significantly trim the revenue per patient for Enbrel. Meanwhile, existing patients may transition to biosimilars, further impacting overall volume and revenue.
Key Factors Impacting Future Pricing
- Patent litigation outcomes: Continued legal disputes may delay biosimilar market entry.
- Regulatory developments: Enhanced approval pathways for biosimilars could accelerate price declines.
- Healthcare policies: Payers emphasize value-based contracting, pressuring list prices.
- Market saturation: Achieved easier with increased biosimilar options available for TNF inhibitors.
Key Takeaways
- The market for Enbrel (NDC 00003-0528) is under significant pressure from biosimilar competition.
- U.S. sales are forecast to decline as biosimilars gain market share, reaching around 70–75% penetration by 2025.
- Prices are projected to decrease by approximately 20-30% over the next three years.
- The overall global market remains sizable but is increasingly driven by cost-containment policies and biosimilar availability.
- Price reductions will affect revenue, particularly for existing brand-name Enbrel sales.
FAQs
Q1: When will biosimilars for Enbrel gain significant market share?
A1: Biosimilars are expected to occupy approximately 70-75% of the market by 2025, driven by patent expiration and regulatory pathways.
Q2: How much are biosimilars likely to cost compared to the original Enbrel?
A2: Biosimilars may sell at 20-30% lower prices, approximately $30,000–$40,000 annually, depending on region and reimbursement policies.
Q3: What are the main factors influencing Enbrel’s price decline?
A3: Patent expiry, biosimilar competition, payer negotiations, and regulatory changes.
Q4: Will existing Enbrel patents extend beyond 2029?
A4: Unlikely, as patents are expected to expire or be challenged, opening the pathway for biosimilar entry.
Q5: How does the market trend impact investment in Enbrel’s manufacturing or R&D?
A5: Investment may decline as revenue stabilizes or decreases, with focus shifting to biosimilar development or next-generation therapies.
References
- Global Market Insights. (2023). Autoimmune Disease Treatment Market Report.
- IQVIA. (2022). Leading Biologic Drugs Sales Data.
- U.S. Food and Drug Administration. (2022). Biosimilar Approvals.
- Evaluate Pharma. (2023). Biologic Market Trends and Forecasts.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement and Pricing Policies.
